An overview of the reclassification of COVID-19 of the Infectious Diseases Control Law in Japan.

IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Global health & medicine Pub Date : 2023-04-30 DOI:10.35772/ghm.2023.01023
Kanako Kitahara, Yoshihiro Nishikawa, Hirokazu Yokoyama, Yoshinobu Kikuchi, Masami Sakoi
{"title":"An overview of the reclassification of COVID-19 of the Infectious Diseases Control Law in Japan.","authors":"Kanako Kitahara,&nbsp;Yoshihiro Nishikawa,&nbsp;Hirokazu Yokoyama,&nbsp;Yoshinobu Kikuchi,&nbsp;Masami Sakoi","doi":"10.35772/ghm.2023.01023","DOIUrl":null,"url":null,"abstract":"<p><p>Japan's responses to COVID-19 have been conducted based on the Act on the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases (the Infectious Diseases Control Law) and the Act on Special Measures against Novel Influenza, <i>etc</i>. (the Act on Special Measures), as COVID-19 is classified as the category of \"the Novel Influenza <i>etc</i>.\" under the Infectious Diseases Control Law. The government's Novel Coronavirus Response Headquarters decided to reclassify COVID-19 as a Category V infectious disease under the Infectious Diseases Control Law in May 2023 since the disease has become less lethal. Accordingly, the countermeasures such as surveillance and medical care are going to be reviewed, and COVID-19 prevention actions will depend on personal choices (Prior to the review in May, mask usage will be changed from 13 March). However, this does not mean that infection control measures are no longer necessary; it is recommended that such measures be taken in certain settings in order to prevent the elderly and those who at a high risk of severe illness from being infected, even after the disease is classified as Category V.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"5 2","pages":"70-74"},"PeriodicalIF":1.9000,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130540/pdf/ghm-5-2-70.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global health & medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35772/ghm.2023.01023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 2

Abstract

Japan's responses to COVID-19 have been conducted based on the Act on the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases (the Infectious Diseases Control Law) and the Act on Special Measures against Novel Influenza, etc. (the Act on Special Measures), as COVID-19 is classified as the category of "the Novel Influenza etc." under the Infectious Diseases Control Law. The government's Novel Coronavirus Response Headquarters decided to reclassify COVID-19 as a Category V infectious disease under the Infectious Diseases Control Law in May 2023 since the disease has become less lethal. Accordingly, the countermeasures such as surveillance and medical care are going to be reviewed, and COVID-19 prevention actions will depend on personal choices (Prior to the review in May, mask usage will be changed from 13 March). However, this does not mean that infection control measures are no longer necessary; it is recommended that such measures be taken in certain settings in order to prevent the elderly and those who at a high risk of severe illness from being infected, even after the disease is classified as Category V.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
日本《传染病防治法》对COVID-19重新分类概述
日本根据《传染病防治法》(《传染病防治法》)和《新型流感特别措施法》(《特别措施法》)采取了应对措施,因为在《传染病防治法》中,新型流感被列为“新型流感等”。政府新型冠状病毒对策本部于2023年5月决定,根据《传染病管理法》,将新冠病毒重新分类为“第五类传染病”。因此,将重新审查监测和医疗等对策,并根据个人选择采取预防措施(在5月审查之前,从3月13日起将改变口罩的使用)。然而,这并不意味着不再需要感染控制措施;建议在某些情况下采取这类措施,以防止老年人和患严重疾病风险高的人受到感染,即使这种疾病被列为第五类。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
7.70%
发文量
0
期刊最新文献
Advances in HIV management and challenges in Japan: Current situation of pre-exposure prophylaxis in Tokyo. Analysis of tumor infiltrating immune cells in Kaposi sarcoma lesions discovers shifts in macrophage populations. Changes in epidemiological and treatment-related characteristics among newly reported HIV/AIDS cases in an urban area in Shanghai, China from 2001 to 2019: A population-based retrospective study. Exploration of PrEP/PEP service delivery model in China: A pilot in eastern, central and western region. Identification of new circulating recombinant form of HIV-1 CRF139_02B in Japan, and search for the origin.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1